QuestionSBA
QuestionChoice
Aspirin achieves its anti-platelet effect by inhibiting the COX-1 enzyme. The mechanism of action of warfarin, an anticoagulant, is inhibiting vitamin K epoxide reductase. This prevents the regeneration of reduced Vitamin K which is needed for clotting factor synthesis.
10003924
d
Vitamin K epoxide reductase inhibitor
QuestionChoice
Aspirin inhibits the COX-1 enzyme. This prevents the conversion of arachidonic acid to prostaglandins. Prostaglandins produced by COX-1 are involved in platelet aggregation. Hence, aspirin reduces platelet aggregation.
10003921
a
COX-1 inhibitor
QuestionChoice
Aspirin achieves its anti-platelet effect by inhibiting the COX-1 enzyme. However, another anti-platelet agent, dipyridamole, achieves part of its anti-platelet effect by inhibiting phosphodiesterase. This increases cAMP levels, causing vasodilation and inhibiting platelet activation and aggregation.
10003923
c
Phosphodiesterase inhibitor
QuestionChoice
Aspirin achieves its anti-platelet effect by inhibiting the COX-1 enzyme. Other anti-platelets, such as clopidogrel and ticagrelor, are P2Y12 receptor antagonists, preventing ADP-mediated platelet aggregation.
10003922
b
P2Y12 receptor antagonist
QuestionChoice
Aspirin achieves its anti-platelet effect by inhibiting the COX-1 enzyme. The mechanism of action of dabigatran, a DOAC, is directly inhibiting thrombin IIa.
10003925
e
Direct Thrombin IIa inhibitor
Concept
Chapter
2693
4216
Aspirin
Topic
169
Cardiovascular pharmacology
13331
A 72-year-old female is admitted to the stroke ward after having an ischaemic stroke. She receives thrombolysis and 24 hours later and is started on 300mg aspirin for 14 days.

What is the mechanism of action of aspirin?
a